714971-09-2

Basic information

• Product Name: AC480 (BMS-599626)
• Synonyms: Carbamic acid, [4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-, (3S)-3-morpholinylmethyl ester (9CI);N-[4-[[1-[(3-Fluorophenyl)Methyl]-1H-indazol-5-yl]aMino]-5-Methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbaMic Acid (3S)-3-MorpholinylMethyl Ester;[(3S)-Morpholin-3-yl]methyl N-[4-[[1-[(3-fluorophenyl)methyl]indazol-5-yl]amino]-5-methyl-pyrrolo;(S)-Morpholin-3-ylmethyl (4-((1-(3-fluorobenzyl)-1H-indazol-5-yl)amino)-5-methylpyrrolo[2,1-f][1,;AC480 (BMS-599626);(S)-morpholin-3-ylmethyl 4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-5-methylpyrrolo[1,2-f][1,2,4]triazin-6-ylcarbamate;(3S)-morpholin-3-ylmethyl N-[4-({1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl}amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate;BMS599626 Free base
• CAS NO: 714971-09-2
• Molecular Formula: C₂₇H₂₇FN₈O₃
• Molecular Weight: 530.561
• Product Categories: Aromatics;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 714971-09-2.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Density: 1.484 g/cm³
• Solubility: ≥28.35 mg/mL in DMSO
• PKA: 7.27±0.46(Predicted)
• CAS DataBase Reference: AC480 (BMS-599626)(CAS DataBase Reference)
• NIST Chemistry Reference: AC480 (BMS-599626)(714971-09-2)
• EPA Substance Registry System: AC480 (BMS-599626)(714971-09-2)

Safety Data

• Hazardous Substances Data: 714971-09-2(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 714971-09-2 differently. You can refer to the following data:
1. BMS-599626 is a highly selective pan-HERKinase inhibitor with IC50 of 20 and 30 nM for the inhibition of HER1and HER2, respectively.
2. It is a highly selective and potent inhibitor of HER1 and HER2 kinases and inhibits tumor cell proliferation through modulation of receptor signaling. BMS-599626 inhibits HER1/HER2 receptor heterodimerization and provides an additional mechanism of inhibiting tumors in which receptor coexpression and heterodimerization play a major role in driving tumor growth.

Biological Activity

ac480 (bms-599626) is a potent, selective inhibitor of human epidermal growth factor receptor (her) that inhibits her1 and her2 with ic values of 20 nm and 30 nm, respectively. ac480 has been proved to inhibit her1 in an atp-competitive manner. on the contrary, ac480 has shown to be an atp noncompetitive inhibitor of her2 [1]ac480 inhibited the proliferation of sal2 cells derived from a transgenic mouse tumor, breast tumor and gastric carcinoma cell lines, geo colon tumor cells, non–small-cell lung tumor cells line via her1 and/or her2 signalings [1].ac480 by oral administration has been demonstrated to suppress the growth of sal2 tumor, geo xenograft tumor, kpl-4 and bt474 breast tumors, n87 gastric tumor, a549 and l2987 non–small-cell lung tumors in nude mice [1].

references

[1] wong tw1, lee fy, yu c, luo fr, oppenheimer s, zhang h, smykla ra, mastalerz h, fink be, hunt jt,gavai av, vite gd. preclinical antitumor activity of bms-599626, a pan-her kinase inhibitor that inhibits her1/her2 homodimer and heterodimer signaling. clin cancer res. 2006 oct 15;12(20 pt 1):6186-93.

Upstream product

• 202197-31-7 1-(3-fluorobenzyl)-1H-indazol-5-ylamine 
• 5401-94-5 5-nitroindazole 
• 106973-37-9 (3S)-5-oxo-4-(phenylmethyl)-3-morpholinecarboxylic acid 
• 714971-27-4 (R)-(4-benzylmorpholin-3-yl)methanol hydrochloride 
• 215917-99-0 (R)-3-(hydroxymethyl)morpholine-4-carboxylic acid tert-butyl ester 
• 856667-80-6 4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid 
• 714971-12-7 (S)-tert-butyl 3-((4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-ylcarbamoyloxy)methyl)morpholine-4-carboxylate 

Relevant articles and documents

SYNTHETIC PROCESS

The present invention provides a process for preparing compounds of formula (I) ["insert chemical structure here"](I)or a pharmaceutically acceptable salt thereof. The compounds prepared by the process of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.